Constitutive Expression of Inter-α-inhibitor (IαI) Family Proteins and Tumor Necrosis Factor-stimulated Gene-6 (TSG-6) by Human Amniotic Membrane Epithelial and Stromal Cells Supporting Formation of the Heavy Chain-Hyaluronan (HC-HA) Complex*

Received for publication, January 17, 2012, and in revised form, February 16, 2012. Published, JBC Papers in Press, February 20, 2012, DOI 10.1074/jbc.M112.342873

Suzhen Zhang†, Hua He‡, Anthony J. Day§¶†, and Scheffer C. G. Tseng†¶§

From the †Ocular Surface Research and Education Foundation, §TissueTech, Inc., and ‡Ocular Surface Center, Miami, Florida 33173 and the ¶Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom

Background: The heavy-chain-hyaluronan (HC-HA) complex from amniotic membrane (AM) has anti-inflammatory, anti-scarring, and anti-angiogenic actions.

Results: AM epithelial and stromal cells constitutively expressed IαI and TSG-6 supporting the production of HC-HA.

Conclusion: AM is an extrahepatic tissue constitutively producing its own IαI and HC-HA complex.

Significance: HC-HA endogenously produced by AM may play an important protective role during fetal development.

Recently, we reported HC-HA, a covalent complex formed between heavy chains (HCs) of inter-α-inhibitor (IαI) and hyaluronan (HA) by the catalytic action of tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6), is responsible for human amniotic membrane (AM) anti-inflammatory, anti-scarring, and anti-angiogenic actions. At the present time, the only well characterized source of IαI is serum being produced by the liver. This study showed that AM epithelial and stromal cells and stromal matrix all stained positively for HA, HC 1, 2, and 3, bikunin, and TSG-6. TSG-6 mRNA and protein were constitutively expressed by cultured AM epithelial and stromal cells without being up-regulated by TNF. In serum-free conditions, these cells expressed IαI, leading to the formation of HC-HA complex that contained both HC1 and HC2. In contrast, only HC1 was found in the HC-HA complex purified from AM. Local production of IαI, the HC-TSG-6 intermediate complex, and HC-HA were abolished when cells were treated with siRNA to HC1, HC2, bikunin (all of which impair the biosynthesis of IαI), or TSG-6 but not to HC3. Collectively, these results indicate that AM is another tissue in addition to the liver to constitutively produce IαI and that the HC-HA complex made by this tissue is different from that found at inflammatory sites (e.g. in asthma and arthritis) and in the matrix of the cumulus oocyte complex.

The human inter-α-inhibitor (IαI) family is a group of plasma serine protease inhibitors that comprise one or two homologous heavy chains (HCs) and one common light chain called bikunin, of which the latter is responsible for the protease inhibitory activity (1, 2). The homologous HCs consist of five members (HC1–5), with HC1, HC3, and HC4 residing in a closely linked region on chromosome 3p21 (3), whereas HC2 and HC5 are arranged in tandem on chromosome 10p15 (4). HC1, HC2, and HC3 contain a conserved proteolytic cleavage site in their C-terminal regions and are able to link to the single chondroitin sulfate (CS) chain of the proteoglycan bikunin via covalent (ester) bonds after they are released from their HC precursor (1, 2, 5, 6). HC4 lacks such a conserved sequence in its C-terminal region, explaining why it does not attach to bikunin and exists as a free HC polypeptide in the blood circulation (7). HC5 apparently has all of the structural features of HC1–3 necessary for the covalent attachment to CS; however, the existence of a HC5-bikunin complex has not been proven (4). The bikunin gene encodes bikunin and another serum protein, α1-microglobulin, which is separated from bikunin after coupling with HCs.

The IαI family proteins are primarily synthesized and assembled in the liver and secreted into the blood circulation. In human plasma, IαI (composed of HC1, HC2, and bikunin) is present at a concentration of 0.15–0.5 mg/ml together with pre-α-inhibitor (Pol, composed of HC3 and bikunin), which has a third of concentration of IαI, and HC2/bikunin (composed of HC2 and bikunin) (8–10). Although the liver is the main site of post-translational modification of the IαI family proteins, expression of individual HCs and bikunin proteins has

* This work was supported, in whole or in part, by National Institutes of Health Grants R44 EY017497 and R43 EY021045 through the NEI (to S. C. G. T.). This work was also supported by a research grant from TissueTech, Inc., and an unrestricted grant from Ocular Surface Research and Education Foundation, Miami, FL.

† Supported by Arthritis Research United Kingdom Grants 18472 and 19489.

‡ To whom correspondence should be addressed: Ocular Surface Center, 7000 SW, 97 Ave., Suite 213, Miami, FL 33173. Tel.: 305-274-1299; Fax: 305-274-1297; E-mail: stseng@ocularsurface.com.

3 The abbreviations used are: IαI, inter-α-inhibitor; AM, amniotic membrane; AMEC, AM epithelial cell; AMSC, AM stromal cell; CS, chondroitin sulfate; HA, hyaluronan; HAase, hyaluronidase; HABP, HA-binding protein; HC, heavy chain; Pol, pre-α-inhibitor; sc, scrambled; SHEM, supplemental hormonal epithelial medium; TSG-6, TNF-stimulated gene-6.
Iost, TSG-6, and HC-HA Expression by Amniotic Membrane Cells

been detected in many other tissues such as lung, kidney, spleen, pancreas, testis, brain, colon, cartilage, and placenta (4, 9, 11–13). During the acute phase of inflammation or stress, the hepatic synthesis of bikunin and HC2 genes is down-regulated, that of HC3 and HC4 genes is up-regulated, whereas that of HC1 gene is not changed (14–16). Thus, bikunin, HC2/bikunin, and I0l molecules are viewed as negative acute phase proteins whereas P0l is a positive one, implying the relevance of the I0l family proteins in inflammation.

Hyaluronan (HA), a high molecular mass (2.0 × 105 to 1.0 × 107 Da) nonsulfated glycosaminoglycan, consists of linear repeating disaccharide units of glucuronosyl-N-acetylgluco-
samine and distributes ubiquitously in the extracellular matrix of vertebrate tissues. Unlike sulfated glycosaminoglycans, HA is not covalently linked to a core protein but does interact nonco-

valently with a wide range of HA-binding proteins, including aggrecan, cartilage link protein, CD44, and tumor necrosis factor (TNF)-stimulated gene-6 (TSG-6) (17). Intriguingly, HC1 aggrecan, cartilage link protein, CD44, and tumor necrosis fac-

ty (21, 27, 28). Although HC-HA complexes are also found at sites of inflammation (11, 12, 39, 40). PepMute siRNA Transfection Reagent was from SignaGen Laboratories (Rockville, MD). The RNasey Mini RNA isolation kit, small interfering RNA (siRNA) oligonucleotides for targeting endogenous human HC1 (UAUAUGUUCUGAGAGUCACTTT) and HC3 (UUG-ACUAUCUGACGUGUCGCA), and nontargeting siRNA

A NEW APPROACH TO THE PRODUCTION OF THERAPEUTIC PROTEINS

EXPERIMENTAL PROCEDURES

Materials—Guandine hydrochloride, cesium chloride, EDTA, anhydrous alcohol, potassium acetate, sodium acetate, sodium chloride, sodium hydroxide, Tris, Triton X-100, 3-(N,N-dimethyl palmityl amino) propanesulfonate (Zwittergent3–16), protease inhibitor mixture (including 4-2(aminooethyl)-benzenesulfonyl fluoride hydrochloride, aprotinin, bestatin hydrochloride, E-64, leupeptin, and pepstatin A) and phenylmethylsulfonyl fluoride were obtained from Sigma-Aldrich. Streptomyces hyaluronidase (HAase), chondroitinase ABC, and biotinylated HA-binding protein (HABP) were from Seikagaku Biobusiness Corporation (Tokyo, Japan). DMEM, Ham’s F12 nutrient mixture, FBS, Hanks’ balanced salt solution, gentamicin, amphotericin B, and radioimmunoprecipitation assay buffer were purchased from Invitrogen. Slide-A-Lyzer dialysis cassettes (3.5K MWCO) were from Fisher Scientific. The BCA protein assay kit was from Pierce. The HA Quantitative Test kit was from Corgenix (Westminster, CO). 4–15% gradient acrylamide ready gels and nitrocellulose membranes were from Bio-Rad.

Mouse anti-human ITIH1 monoclonal antibody against full-

length ITIH1 and rabbit anti-human bikunin polyclonal antibody against full-length bikunin were from Abcam (Cambridge, MA). The recombinant human TSG-6 protein (TSG-6Q) (39) and rabbit antiserum against the C-terminal peptide of human TSG-6 (RAH-1, TSTGNKFLAGRFSHL), the N-terminal peptides of human HC2 (SLPGESEEMM) and HC3 (SLPGVANG), and the C-terminal peptide of human HC2 (ESTPPPHVMRVE) were as described previ-

ously (11, 12, 39, 40). PepMute™ siRNA Transfection Re-

agent was from SignaGen Laboratories (Rockville, MD). The RNasey Mini RNA isolation kit, small interfering RNA (siRNA) oligonucleotides for targeting endogenous human HC1 (UAUAUGUUCUGAGAGUCACTTT) and HC3 (UUG-ACUAUCUGACGUGUCGCA), and nontargeting siRNA

control oligonucleotides (scrambled RNA) were from Qia-

gen (Valencia, CA). siRNA oligonucleotide for targeting endogenous human TSG-6 (GGUUUCCAAAUCAAAUAUGGUCCAA), HC2 (GGAGCAUUAGAGACGGUGUGAACG), and bikunin (GGGUUAUCAGAAGCUAGUCACCAT) were from OriGene Technologies (Rockville, MD). Western Lighting™ Chemiluminescence Reagent was from PerkinElmer Life Sciences. The ultracentrifuge (LM8 model, SW41 rotor) was from Beckman Coulter.

Cell Cultures—Human tissue was handled according to the Declaration of Helsinki. The fresh human placenta was obtained from healthy mothers after elective cesarean deliver-

ies in the Baptist Hospital (Miami, FL) via an approval (Protocol 03-028) by the Baptist Health South Florida Institutional Review Board. Primary human AM epithelial and stromal cells (designated as AMECs and AMSCs, respectively) were isolated from fresh placenta as described previously (41, 42) and cul-

tured in supplemental hormonal epithelial medium (SHEM), which consisted of DMEM/F12 (1:1, v/v), 5% (v/v) FBS, 0.5% (v/v) dimethyl sulfoxide, 2 ng/ml EGF, 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml sodium selenite, 0.5 μg/ml hydrocortisone, 0.1 nM cholera toxin, 50 μg/ml gentamicin, 1.25 μg/ml amphotericin B) (41, 43) under a humidified atmosphere of 5% CO2 at 37 °C. The culture medium was changed every 2 days. At sub-

confluence, cells were incubated in SHEM containing 20 ng/ml TNF for 4 or 24 h prior to RT-PCR or Western blot analysis. In experiments for TSG-6 detection, AMECs, AMSCs, and human skin fibroblasts were cultured in DMEM/F12 containing 10% FBS medium (i.e. to prevent the influence of other components such as EGF in SHEM on TSG-6 expression). To exclude serum I0l, serum-free cultures were established with secondary cul-

tures. After seeding and attachment, cells were washed three times with Hanks’ balanced salt solution and switched to fresh SHEM without serum, and the serum-free medium was changed every 2 days until experimental manipulation.
siRNA Transfection—AMECs and AMSCs were cultured in serum-free SHEM in 6-well plates until 50–60% confluence, when cells were transfected with PepMute™ siRNA Transfection Reagent with or without 10 mM HC1 siRNA, HC2 siRNA, bikunin siRNA, HC3 siRNA, or scrambled (sc) RNA. After 48 h, cells were harvested and subjected to RT-PCR and Western blot analysis. For TSG-6 detection, AMECs and AMSCs were cultured in DMEM/F12 containing 10% FBS medium and transfected with TSG-6 siRNA or scRNA.

Purification of HC-HA Complex from AM and Serum-free Cultures by Ultracentrifugation—HC-HA complex was purified from AM and serum-free cultures as described previously (32, 44, 45). For purification of HC-HA complex from AM, cryopreserved human AM, obtained from Bio-tissue (Miami, FL), was sliced into small pieces, frozen in liquid nitrogen, and cryopreserved at 0 °C for 1 h. The cryopreserved AM was then mixed with a 8M guanidine HCl/PBS solution (at 1:1 ratio of v/v) containing 10 mM EDTA, 10 mM aminocaproic acid, 10 mM N-ethylmaleimide, and 2 mM PMSF (45). For purification of HC-HA complex from serum-free cultures, cells were washed three times with Hank’s balanced salt solution and extracted with 6 M guanidine HCl, 0.2 w/v Tris-HCl (pH 8.0), 0.1% (w/v) Zwittergent® containing protein inhibitors (10 mM EDTA, 10 mM aminocaproic acid, 10 mM N-ethylmaleimide, and 2 mM PMSF) (44). The cell extract was kept at 4 °C overnight with gentle stirring before removing the insoluble materials by centrifugation at 14,000 g for 30 min at 4 °C. The supernatant (designated as AM extract) was then mixed with a 8M guanidine HCl/PBS solution (at 1:1 ratio of v/v) containing 10 mM EDTA, 10 mM aminocaproic acid, 10 mM N-ethylmaleimide, and 2 mM PMSF (44). The cell extract was kept at 4 °C overnight with gentle stirring before removing the insoluble materials by centrifugation at 14,000 g for 30 min at 4 °C. The supernatant (designated as AM extract) was then mixed with a 8M guanidine HCl/PBS solution (at 1:1 ratio of v/v) containing 10 mM EDTA, 10 mM aminocaproic acid, 10 mM N-ethylmaleimide, and 2 mM PMSF (44). The cell extract was kept at 4 °C overnight with gentle stirring before removing the insoluble materials by centrifugation at 14,000 g for 30 min at 4 °C. The above extracts were adjusted to a density of 1.35 g/ml (AM extract) or 1.40 g/ml (cell extract) with cesium chloride, respectively, and subjected to isopycnic centrifugation at 35,000 rpm, 15 °C, for 48 h. The resultant density gradients were fractionated into 12 tubes (1 ml/tube), in which the contents of HA and proteins were measured using HA Quantitative Test kit and BCA protein assay kit, respectively. Fractions from the first ultracentrifugation, which contained most HA, were pooled, brought to a density of 1.40 g/ml (AM extract) or 1.45 g/ml (cell extract) by addition of CsCl, ultracentrifuged, and fractionated in the same manner as described above. Fractions from the second ultracentrifugation, which contained HA but no detectable proteins, were pooled and dialyzed in distilled water and then precipitated twice with 3 volumes of 95% (v/v) ethanol containing 1.3% (w/v) potassium acetate at 0 °C for 1 h. After centrifugation at 15,000 × g, the pellet was briefly dried by air, stored at −80 °C, and designated as AM HC-HA complex and cell HC-HA complex, respectively.

Immunofluorescence Analysis—Human fetal membrane containing AM and chorion was cryosectioned to 5-μm thickness, fixed with 4% paraformaldehyde at room temperature for 15 min, and permeabilized with 0.2% (v/v) Triton X-100 in PBS for 20 min. After blocking with 0.2% (w/v) BSA in PBS for 1 h, sections were incubated with biotinylated HABP (for HA, 5 μg/ml) or different primary antibodies specific for HC1, HC2, HC3, bikunin, and TSG-6 (all diluted 1:200 in blocking solution) overnight in a humidity chamber at 4 °C. For HC2, we used an anti-N-terminal HC2 antibody throughout unless mentioned otherwise. For TSG-6, we used MAB2104 throughout unless mentioned otherwise. After washing with PBS, they were incubated with Alexa Fluor 488 streptavidin (for HA, diluted 1:100), or respective secondary antibodies (i.e. FITC-conjugated anti-mouse IgG, or FITC-conjugated anti-rabbit IgG) for 1 h at room temperature. Isotype-matched nonspecific IgG antibodies were used as a control. Alternatively, sections were treated with 50 units/ml Streptomyces HAase at 37 °C for 4 h before fixation. Nuclei were stained by Hoechst 33342, and images were obtained using a Zeiss LSM700 confocal laser scanning microscope (Zeiss, Germany).

RT-PCR—Total RNA was extracted from AM tissue and cell cultures using a RNeasy Mini RNA isolation kit. The cDNA was reverse-transcribed from 1 μg of total RNA using a Cloned AMW First-Strand cDNA synthesis kit with gene-specific antisense primer (for HC1–3 and bikunin) (Table 1) or oligo(dT) primer (for TSG-6). First-strand cDNAs were amplified by PCR using AmpliTaq Gold Fast PCR Master Mix and the specific gene primers (Table 1) (46–48). Gliceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression was used to normalize the amounts of the amplified products. The PCR products were electrophoresed on a 2% (w/v) agarose gel with ethidium bromide staining, photographed using the UVP Biolmaging system, and analyzed using the ImageJ software (Java).

Western Blotting—Culture supernatants were collected, and cell lysates were obtained by washing cells six times with cold PBS followed by incubating in radioimmunoprecipitation assay buffer at 4 °C for 1 h with gentle stirring and centrifugation at 4,000 × g for 15 min. The supernatants were stored at −80 °C until use. Blots were incubated with either of specific antibodies (i.e. HABP for HA, 1:500; anti-N-terminal HC2 for HC2, 1:250; anti-N-terminal HC3 for HC3, bikunin, and TSG-6, 1:200; anti-N-terminal HC4 for HC4; anti-N-terminal HC5 for HC5) or respective secondary antibodies (i.e. HRP-conjugated anti-mouse IgG, or HRP-conjugated anti-rabbit IgG) for 1 h at room temperature. Isotype-matched nonspecific IgG antibodies were used as a control.
14,000 × g for 30 min at 4 °C. Protein concentrations in culture supernatants and cell lysates were quantified with a BCA protein assay kit. For alkaline treatment of AM extract, samples were incubated in 50 mM NaOH for 1 h at 25 °C. For HAase digestion of the HC-HA complex, samples were dissolved in 0.1 M sodium acetate buffer (pH 6.0) and incubated at 60 °C for 1 h with or without 20 units/ml Streptomyces HAase. The above samples were resolved by SDS-PAGE on 4–15% (w/v) gradient acrylamide ready gels under denaturing and reducing conditions and transferred to a nitrocellulose membrane. The membrane was then blocked with 5% (w/v) fat-free milk in 50 mM Tris-HCl (pH 7.5) buffer containing 150 mM NaCl and 0.05% (v/v) Tween 20 followed by sequential incubation with different primary antibodies followed by their respective HRP-conjugated secondary antibodies. Immunoreactive proteins were visualized by Western Lightning™ Chemiluminescence reagent.

RESULTS

Immunolocalization of HA, HCs, Bikunin, and TSG-6 in Human AM—To address whether the AM could produce its own Iol to form HC-HA complex, we first investigated whether the required components, i.e. HA, each individual HC, bikunin, and TSG-6, were actually present in human AM in vivo. Frozen sections of the fetal membrane revealed AM consisting of a simple epithelium and an avascular stroma and subjacent cell-rich chorion (Fig. 1, Phase). Consistent with what has been reported previously (49, 50), strong positive HA immunostaining was noted in AM stroma and relatively weak staining in AM epithelium using a biotinylated HABP (Fig. 1, HA). This staining was lost when the tissue section was predigested by HAase (Fig. 1, HA (HAase)) indicating that HA staining is specific. Immunostaining of each individual HC using specific antibodies also revealed a positive staining in AM epithelium, stromal cells, and/or stromal matrix (Fig. 1, HC1, HC2, and HC3). Positive bikunin immunostaining was found in the apical surface of the epithelium, the basement membrane zone, and the stroma (Fig. 1, Bikunin). TSG-6 immunostaining with two different anti-TSG-6 antibodies, i.e. MAB2104 (Fig. 1, TSG-6) and RAH-1 (data not shown) showed the same pattern with positive staining associated with AMECs, AMSCs, and stromal matrix. The lack of immunoreactivity by nonimmune control serum indicates that the staining described above is specific. Collectively, these results suggested the presence of all components in AM required for forming Iol, Pol, and HC-HA.

Presence of Individual HCs, Bikunin, TSG-6, Pol, and Iol in AM-soluble Extract—To investigate further the presence of the above components in AM, we performed Western blotting analyses of proteins extracted by an isotonic salt buffer before and after 50 mM NaOH treatment to cleave ester bonds (20, 32, 44, 51). Using anti-HC1, HC2, or bikunin antibodies, purified Iol was found to contain a major 250-kDa species corresponding to intact Iol and several weak species of smaller molecular mass most likely representing intermediate species (Fig. 2, lanes 2, 4, and 6), including a free HC1 species of 75 kDa (lane 2).
NaOH treatment of the Iol preparation released HC1 (75 kDa, lane 3), HC2 (80 kDa, lane 5), and bikunin as 35-kDa and 22-kDa species (lane 7). The latter two species likely correspond to bikunin with and without an attached CS chain (11, 52). When purified Iol was treated with chondroitinase ABC lyase, only the 22-kDa species was observed with the anti-bikunin antibody (lane 8) (53, 54). Purified bikunin, which appeared as a 35-kDa species (lane 9), yielded both 35-kDa and 22-kDa species after the same NaOH treatment (lane 10), but gave rise to only the 22-kDa species after chondroitinase ABC lyase treatment (lane 11). These results confirmed that both 35-kDa and 22-kDa bikunin species formed after mild NaOH treatment of Iol (i.e. with partial release of the CS chain). Based on the profile generated by both Iol and bikunin controls, we detected the 250-kDa Iol species and its components, HC1, HC2, and bikunin in AM-soluble extract (lanes 12, 14, and 18). The antibikunin antibody also reacted with a 130-kDa species (lane 18), which was likely Pol because it was detected by an anti-HC3 antibody that also recognized a free HC3 species of 80 kDa (lane 16). The identity of Iol and Pol was further verified by the NaOH treatment, which released corresponding HCs and bikunin species that were detected by the various chain-specific antibodies (lanes 13, 15, 17, and 19). A similar result was also obtained with an anti-Iol antibody (data not shown). Because Iol/Pol chain-specific antibodies and the anti-Iol antibody all reacted with a 50-kDa species, which was also detected by normal mouse or rabbit serum (data not shown), we concluded that this 50-kDa species was nonspecific.

Analysis of the AM extract with an anti-TSG-6 antibody (MAB2104) revealed a species of ~35 kDa (lane 21), which corresponds to the expected size of native TSG-6 (25), which is slightly larger than the size of recombinant TSG-6 (TSG-6Q, 32 kDa) (lane 20) (39) that has a lower level of glycosylation (32). This antibody also detected a major 50-kDa species, where neither this nor the ~35-kDa species was affected by NaOH treatment (i.e. in agreement with our previous report (32) using three different anti-TSG-6 antibodies). Again, the detection of the 50-kDa species is likely nonspecific. Taken together, these results demonstrated that the soluble AM extract indeed contained Iol, Pol, HC1, HC2, HC3, bikunin, and TSG-6.

Constitutive Expression of HC1, HC2, HC3, and Bikunin mRNA and Proteins by AMECs and AMSCs in Serum-containing Media—To provide data on the cellular sources of HC1, HC2, HC3, and bikunin, we established primary cultures of AMECs and AMSCs in SHEM, which was found to be the optimal medium in our prior study (41), and extracted total RNA for RT-PCR and proteins for Western blot analysis. The positive control of human liver RNA yielded PCR products with the expected sizes of 138 bp (HC1), 127 bp (HC2), 318 bp (HC3), and 294 bp (bikunin) (Fig. 3A). These four RT-PCR products were all present in AM tissue as well as both AMECs and AMSCs. The expression of HCs and bikunin transcripts was not greatly up-regulated by TNF in AMECs and AMSCs. Western blotting of AMEC and AMSC lysates showed that a 265-kDa and a 200-kDa species were recognized by the chain-specific antibodies against HC1, HC2, and bikunin (Fig. 3, B, C, and D) but not by anti-HC3 (Fig. 3E), suggesting that these two species were Iol-related. Anti-HC1, anti-HC2, and anti-HC3 antibodies all recognized ~75-kDa species (Fig. 3, B, C, and E); the anti-bikunin antibody detected a 35-kDa species (Fig. 3D).

Thus, based on our comparison with purified Iol and a serum control (as a source of Pol), and with published data (52, 55), AMECs and AMSCs can be concluded to express HC1, HC2, HC3, and bikunin proteins. In addition, both anti-HC1 (Fig. 3B) and anti-HC2 antibodies (Fig. 3C) also recognized 120-kDa species that are likely HC1-TSG-6 and HC2-TSG-6 complexes, respectively (see below) (18, 23, 56). Based on prior reports (52, 55), the 100-kDa species revealed by anti-HC1, anti-HC2, and anti-HC3 antibodies were likely HC1, HC2, and HC3 precursors, respectively. Approximately 45–90-kDa species revealed by anti-bikunin are likely to be bikunin precursor (i.e. α₁-microglobulin/bikunin tandem protein) with or without glycosaminoglycan attached, a finding also observed in primary rat hepatocytes (54). The identities of HC1- and HC2-positive species at 65 and 50 kDa (Fig. 3, B and C) and the faint HC3-positive species at 50 kDa (Fig. 3E) are not clear because these species were also present in serum-free AMEC and AMSC lysates (see below); they were likely not derived from serum. Interestingly, the intensities of the various HC and Iol species were not notably affected by addition of TNF. Overall, these results indicate that AMEC and AMSC produce individual HC1, HC2, and bikunin chains that are assembled into Iol proteins.

Production of Iol Family Proteins in Serum-free AMEC and AMSC Cultures—To avoid undue influence by serum Iol and to provide further evidence for the cellular production of Iol family proteins by AMECs and AMSCs, we harvested cell lysates from their respective serum-free cultures. We also treated these two serum-free cultures with HC1 siRNA, HC2 siRNA, and bikunin siRNA (i.e. because HC1, HC2, and bikunin are components of Iol); as a comparison, we also treated cells with HC3 siRNA because HC3 is not a part of Iol. RT-PCR analysis confirmed the efficiency of these siRNAs to down-regulate their respective transcripts in these two cultures (Fig. 4A). Western blot analysis showed that the 265-kDa and 200-kDa species were significantly reduced by HC1 siRNA, HC2 siRNA, and bikunin siRNA (Fig. 4B), but not by HC3 siRNA (Fig. 4C). The production of HC1, HC2, and bikunin (and their putative precursors) was notably down-regulated by their respective siRNA (Fig. 4B). In addition, the 120-kDa species recognized by anti-HC1 and anti-HC2 antibodies that likely corresponded to respective HC1-TSG-6 and HC2-TSG-6 complexes was decreased by HC1 siRNA and HC2 siRNA, respectively (Fig. 4B). The HC3 siRNA decreased the HC3 species but did not affect the aforementioned species (Fig. 4C), consistent with the inhibitory effects of the siRNAs against HC1, HC2, and bikunin, shown in Fig. 4B, being specific. Essentially the same results were obtained using AMSCs (data not shown). These results collectively provided further evidence that AMECs and AMSCs produced HC1, HC2, and bikunin proteins, which assemble to form Iol.

Constitutive Expression of TSG-6 mRNA and Protein by AMECs and AMSCs—Previous studies have shown that adult skin fibroblasts and peripheral blood mononuclear cells (24, 25, 57, 58), myeloid dendritic cells (59, 60), renal tubular epithelial
cells (61), articular chondrocytes (25, 62, 63), as well as cervical smooth muscle cells (40) express TSG-6 mRNA and protein only under the stimulation of pro-inflammatory cytokine such as TNF and IL-1. To provide further evidence for the cellular sources of TSG-6, we cultured AMECs and AMSCs in DMEM/F12 with 10% FBS to prevent the influence of other components such as EGF in SHEM on TSG-6 expression. As expected, expression of TSG-6 mRNA by human skin fibroblasts was negative but significantly up-regulated by 20 ng/ml TNF (Fig. 5A). In contrast, there was constitutive expression of TSG-6 mRNA by AMECs and AMSCs without being affected by TNF (Fig. 5A). TSG-6 mRNA was also detected in RNAs extracted from fresh AM tissue (Fig. 5A). Western blot analyses of lysates detected four species, i.e. 35, 50, 100, and 120 kDa, in both AMECs and AMSCs, but only 35 kDa and two faint species of 50 and 100 kDa in skin fibroblasts (Fig. 5B). Addition of TNF did not change any species in AMECs and AMSCs, but up-regulated the 35-kDa species (but not the 50- or 100-kDa species) in skin fibroblasts (Fig. 5B). In supernatants, we detected 35-, 100-, 120-, and 150-kDa species (but not 50 kDa) in skin fibroblasts (Fig. 5C); after TNF stimulation, the 100- and 150-kDa species did not change, but 35- and 120-kDa species became intensified. All of these species were also detected in AMEC and AMSC supernatants, where 35- and 120-kDa species were unaffected by TNF.

TSG-6 siRNA transfection greatly reduced both 35- and 120-kDa species in both lysates and supernatants of AMEC but did not affect the 50- and 100-kDa species in cell lysates (Fig. 5D) or the 100- and 150-kDa species in supernatants (Fig. 5E). The same result was observed in AMSCs (data not shown). From these experiments we concluded that the 35-kDa species corresponded to TSG-6 secreted by AMECs and AMSCs, where its production was induced by TNF in skin fibroblasts but was constitutive in AMECs and AMSCs. On the basis of earlier reports (18, 23, 56), the 120-kDa species likely corresponded to the covalent complexes of TSG-6 with HCs. Because the 50-, 100-, and 150-kDa species were not affected by TSG-6 siRNA and because the amounts of these species were not altered by TNF in skin fibroblasts, they were concluded to be nonspecific.
Cellular Production of HC-HA Complex Containing Both HC1 and HC2 whereas AM HC-HA Complex Contains Only HC1—Previous studies have shown that HC1 and HC2 of I/H9251 and HC3 of P/H9251 can covalently bind to HA in vivo and in vitro to form HC-HA complex (19, 20, 64). Our prior study showed that a HC-HA complex can be purified from the AM-soluble extract (32). However, it remained unclear whether bikunin or TSG-6 was also present and which HC isotypes were present in AM HC-HA complex. Because AMECs and AMSCs were found here to synthesize their own I/H9251 and TSG-6 proteins (Figs. 4 and 5), we aimed to determine further whether they could also produce their own HC-HA complex.

We used two successive ultracentrifugations to isolate the HC-HA complex from the AM extract as reported previously (32) and from both cellular extracts (Fig. 6A). Western blot analysis using the anti-HC1 antibody showed that AM HC-HA complex presented as a high molecular mass species at the bottom of the loading well and free HC1 (Fig. 6B, lane 3) by comparison with purified I/H9251 treated with NaOH (Fig. 6B, lanes 1 and 2). HAase digestion completely eliminated the high molecular mass species, resulting in a notable increase in the intensity of the HC1 species (Fig. 6B, lane 4), confirming that the high molecular mass species represented a HC-HA complex. The presence of free HC1 in the AM HC-HA complex might be due to the degradation of HA that lead to release of some HC1 during purification and storage of the complex. Interestingly, the anti-HC2 antibody (raised against the N-terminal peptide) (12) did not detect any species in the AM HC-HA complex with or without HAase digestion (Fig. 6B, lanes 9 and 10) but did detect a HC2 species in I/H9251 (Fig. 6B, lane 8). The same result was obtained using an alternative anti-HC2 antibody raised against the C-terminal peptide (12) (Fig. 6B, lanes 13–16). Preliminary
mass spectrometric analysis of the AM HC-HA complex following digestion with HAase and trypsin detected peptides from HC1 but not from HC2 consistent with the absence of HC2 in AM HC-HA complex. Furthermore, by Western blotting we did not find HC3, bikunin, or TSG-6 in the AM HC-HA complex (data not shown); the absence of bikunin and TSG-6 in the HC-HA complex is in agreement with our previous data (32) and with reports on HC-HA obtained from other sources (31, 65).

Overall, the above results indicate that the HC-HA complex from AM only contains HC1. However, Western blot analysis of the aforementioned cell HC-HA revealed the presence of both HC1 and HC2 after HAase digestion of material purified from both AMSCs (Fig. 6, lanes 5, 6, 11, 12, 17, and 18) and AMECs (data not shown) although the amount increased for HC1 was not as dramatic as HC2. These results indicated that both cells primarily make HC2-HA. We also did not detect HC3, bikunin, and TSG-6 in the cell HC-HA complex (data not shown). The formation of this HC-HA complex was abolished when cells were treated by HC1 siRNA (Fig. 6B, lanes 21 and 22) and TSG-6 siRNA (Fig. 6B, lanes 23 and 24). Available evidence suggests that the covalent coupling of HCs to the CS chain of bikunin to form intact Iα/Iβ is a prerequisite for the subsequent transfer of HCs to HA (23, 27, 64). We found that HC1-siRNA was specific for HC1 but did not affect HC2 and bikunin mRNA expression and their protein synthesis in AMEC and AMSC (data not shown), but prevented the formation of intact Iα/Iβ. So, HC1-siRNA treatment prevents any type of HC-HA formation due to the inhibition of Iα/Iβ biosynthesis caused by HC1 knockdown.

**DISCUSSION**

Previous studies have demonstrated that the Iα/Iβ family proteins are synthesized predominantly by hepatocytes (9, 66) where coupling of HCs and bikunin is accomplished before being secreted into blood circulation (67, 68). Here, for the first time, we have demonstrated that the AM is an extrahepatic tissue that can produce its own Iα/Iβ family proteins. This assertion was suggested by positive immunostaining to HC1, HC2, HC3, and bikunin in AM cells and matrix (Fig. 1) and by the presence of HC1, HC2, HC3, and bikunin transcripts in AM tissues and the respective proteins in AM extract (Figs. 2 and 5). Both 200-kDa and 265-kDa Iα/Iβ-related species produced by AMECs and AMSCs were cross-reactive with anti-HC1, anti-HC2, and anti-bikunin antibodies but not with the anti-HC3 antibody (Figs. 3 and 4). More importantly, these two Iα/Iβ-related species were greatly reduced by knockdown with HC1 siRNA, HC2 siRNA, and bikunin siRNA but not HC3 siRNA (Fig. 4). The apparent molecular masses of the two Iα/Iβ-related species are different from that of

---

4 R. D. Unwin, D. C. Briggs, S. Zhang, H. He, S. C. G. Tseng, and A. J. Day, unpublished data.
I synthesized by primary hepatocytes (225 kDa) (52) and from the H9251 present in AM extract (250 kDa), which is the same size as the H9251 control purified from serum. Cultured AMECs and AMSCs produced an H9251 with an apparent molecular mass of 200 kDa, which is smaller than that found in AM (Fig. 2). Furthermore, HC1 and HC2 released from cell HC-HA were smaller than those released from serum H9251 (and AM HC-HA in the case of HC1) (Fig. 6), as has been found previously for the 70-kDa HC2 from HepG2 cells (52). Such differences are likely explained by differential glycosylation of H9251 from different cell sources (69).

Previous studies have shown that TSG-6 mRNA and protein are not constitutively expressed in many adult cells but is induced by pro-inflammatory cytokines such as IL-1 and TNF (for review, see Ref. 26). Indeed, cultured adult human skin fibroblasts did not express TSG-6 until TNF was added (Fig. 5). In contrast, for the first time, we noted that TSG-6 mRNA was constitutively expressed in fresh AM tissue (Fig. 5), and TSG-6 protein was detected in AM extract (Fig. 2). Moreover, TSG-6 mRNA and protein were constitutively expressed by AMECs and AMSCs without being significantly up-regulated by TNF (Fig. 5). It has also been found that TSG-6 is constitutively expressed by human neutrophils (and then stored in specific granules) (59) and is present in murine bone marrow (this probably corresponds to the presence of polymorphonuclear leukocytes) (70), in human intervertebral disc (71), in human skin (72), and in human periprosthetic breast capsule tissue (73); TSG-6 may play a protective role in some or all of these settings. Because the AM has been shown to be an excellent source of mesenchymal stem cells (for review, see Refs. 74, 75) and because expression of TSG-6 has been reported to be a hallmark for delivering the therapeutic effect of engrafted mesenchymal stem cells (e.g. in a model of myocardial infarction) (76), the constitutive expression of TSG-6 in AM may also contribute to an anti-inflammatory and protective role in the ocular surface.

TSG-6, however, may have other more crucial role in AM. One well known action of TSG-6 is to catalyze the trans-esterification reactions that form the HC-HA complex (11, 21–23); that is, HCs of H9251 are transferred from CS to HA with the release of bikunin. For the HC-HA complex found in the cumulus matrix of preovulatory follicles (77–79) and the synovial fluid of rheumatoid arthritis patients (20, 29), the source of HCs is believed to be from serum H9251. The constitutive presence of both H9251 and TSG-6 in AM extract and production by both AMECs and AMSCs in serum-free cultures (Figs. 4 and 5) suggest that the HC-HA complex can endogenously be produced by these two AM cells without serum participation. Indeed, the HC-HA complex was purified by two successive ultracentrifugations from the guanidine-HCl-extracted lysates in serum-free AMEC and AMSC cultures (Fig. 6). Furthermore, the production of such an HC-HA complex was abolished when cells were treated with siRNA to TSG-6 or HC1 (Fig. 6). In cumulus matrix and pathological synovial fluid, all three HC isoforms (HC1, HC2, and HC3) have been found to form covalent complexes with HA (18, 20). Our study showed that both HC1 and HC2 were incorporated in cell HC-HA complex, whereas only HC1 was covalently bound to HA in the AM HC-HA complex (Fig. 6). The absence of HC2 was verified by both anti-C- and anti-N-terminal antibodies and was consist-
ent with our initial mass spectrometric analysis. Future studies are needed to delineate how the in vivo biosynthetic environment might favor the formation of the HC-HA complex with specific compositions (e.g., just HCl) to yield unique physiological actions.

The HC-HA complex purified from AM exerts potent anti-inflammatory, anti-scarring, and anti-angiogenic actions (32, 33), explaining why transplantation of cryopreserved AM is effective for treating a number of ocular surface diseases. Herein, our study provides strong evidence that the AM can produce endogenous I\(\alpha\)l and TSG-6 proteins that can support the formation of its own HC-HA complex. Given that AM is avascular, locally produced HC-HA complex may play a crucial protective role during fetal development.

REFERENCES

1. Blom, A. M., Mörgelin, M., Oyen, M., Jarvet, J., and Fries, E. (1999) Structural characterization of inter-α-inhibitor: evidence for an extended shape. J. Biol. Chem. 274, 298–304

2. Enghild, J. J., Thøgersen, I. B., Pizzo, S. V., and Salvesen, G. (1989) Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma: polypeptide chain stoichiometry and assembly by glycan. J. Biol. Chem. 264, 15975–15981

3. Diarra-Mehrpour, M., Sarafan, N., Bourguignon, J., Bonnet, F., Bost, F., and Martin, J. P. (1998) Human inter-α-trypsin inhibitor heavy chain H3 gene: genomic organization, promoter analysis, and gene linkage. J. Biol. Chem. 273, 26809–26819

4. Himmelfarb, M., Klopocki, E., Grube, S., Staub, E., Klaman, I., Hinzmann, B., Kristiansen, G., Rosenthal, A., Dürst, M., and Dahl, E. (2004) ITIH5, a novel member of the inter-α-trypsin inhibitor heavy chain family, is down-regulated in breast cancer. Cancer Lett. 204, 69–77

5. Enghild, J. J., Salvesen, G., Hefta, S. A., Thøgersen, I. B., Rutherford, S., and Pizzo, S. V. (1991) Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-α-inhibitor. J. Biol. Chem. 266, 747–751

6. Jessen, T. E., Faarvang, K. L., and Ploug, M. (1989) Carbohydrate as covalent cross-link in human inter-α-trypsin inhibitor: a novel plasma protein structure. FEBS Lett. 230, 195–200

7. Pu, X. P., Iwamoto, A., Nishihara, M., and Nagasawa, S. (1994) Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma. Biochim. Biophys. Acta 1208, 338–343

8. Mison, C., Balduyck, M., Albani, D., Michalski, C., Burnouf, T., and Mison, J. (1996) Development of an enzyme-linked immunosorbent assay for human plasma inter-α-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. J. Immunol. Methods 190, 61–70

9. Mizushima, S., Nii, A., Kato, K., and Uemura, A. (1998) Gene expression of the two heavy chains and one light chain forming the inter-α-trypsin-inhibitor in human tissues. Biol. Pharm. Bull. 21, 167–169

10. Odum, L. (1990) Inter-α-trypsin inhibitor and pre-α-trypsin inhibitor in health and disease: determination by immunoelectrophoresis and immuno blotting. Biol. Chem. Hoppe Seyler 371, 1153–1158

11. Forteza, R., Casalino-Matsu, S. M., Monzon, M. E., Fries, E., Rugg, M. S., Milner, C. M., and Day, A. J. (2007) TSG-6 potentiates the antitissue inhibitor function of its own HC-HA complex. Biochem. Biophys. Res. Commun. 385, 1154–1160

12. Yoshida, Y., Plaas, A., Osborn, B., Margulis, A., Nelson, F., Stewart, M., Rugg, M. S., Milner, C. M., Day, A. J., Nemoto, K., and Sandy, J. D. (2008) Superficial zone chondrocytes in normal and osteoarthritis human articular cartilage show novel truncated forms of inter-α-trypsin inhibitor heavy chains which are attached to a chondroitin sulfate proteoglycan other than bikunin. Osteoarthritis Cartilage 16, 1343–1355

13. Hamm, A., Veek, J., Bektas, N., Wild, P. J., Hartmann, A., Heindrichs, U., Kristiansen, G., Werbowetski-Ogilvie, T., Del Maestro, R., Knechel, R., and Dahl, E. (2008) Frequent expression loss of inter-α-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 8, 25

14. Daveau, M., Rout, P., Scott, M., Faye, L., Hiron, M., Lebrun, J. P., and Salier, J. P. (1993) Human inter-α-inhibitor family in inflammation: simultaneous synthesis of positive and negative acute-phase proteins. Biochem. J. 292, 485–492

15. Piñeiro, M., Alava, M. A., González-Ramón, N., Osada, J., Lasierra, P., Larrad, L., Piñeiro, A., and Lampreave, F. (1999) TSHH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem. Biophys. Res. Commun. 263, 224–229

16. Day, A. J., and Prestwich, G. D. (2002) Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 277, 4585–4588

17. Mukhopadhyay, D., Hascall, V. C., Day, A. J., Salustri, A., and Fülöp, C. (2001) Two distinct populations of tumor necrosis factor-stimulated gene-6 protein in the extracellular matrix of expanded mouse cumulus cell-oocyte complexes. Arch. Biochem. Biophys. 394, 173–181

18. Law, C., Yee, A., Van der Kooy, M., Amin, S., Wei, R., Vega, P., and Wallingford, J. B. (2001) Expression of the I\(\alpha\)l and TSG-6 genes is regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem. Biophys. Res. Commun. 281, 20303–20314
32. He, H., Li, W., Teng, D. Y., Zhang, S., Chen, S. Y., Day, A. J., and Tseng, S. C. (2009) Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-α-inhibitor (HCA-HA) purified from extracts of human amniotic membrane. J. Biol. Chem. 284, 20136–20146

33. Shay, E., He, H., Sakurai, S., and Tseng, S. C. (2011) Inhibition of angiogenesis by HCA-HA, a complex of hyaluronan and the heavy chain of inter-α-inhibitor, purified from human amniotic membrane. Invest. Ophthalmo. Vis. Sci. 52, 2669–2678

34. Bouchard, C. S., and John, T. (2004) Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocular Surface 2, 201–211

35. Dua, H. S., Gomes, J. A., King, A. J., and Maharajan, V. S. (2004) The amniotic membrane in ophthalmology. Surv. Ophthalmol. 49, 51–77

36. Tseng, S. C. (2001) Amniotic membrane transplantation for ocular surface reconstruction. Bioch. Rep. 21, 481–489

37. Tseng, S. C., Espana, E. M., Kawakita, T., DiPascale, M. A., Li, W., He, H., Liu, T.-S., Cho, T.-H., Gao, Y.-Y., Yeh, L.-K., and Liu, C.-Y. (2004) How does amniotic membrane work? Ocular Surface 2, 177–187

38. Muramatu, M., Mori, S., Matsuzaawa, Y., Horiguchi, Y., Nakashima, Y., and Tanaka, M. (1980) Purification and characterization of urinary trypsin inhibitor, UTI68, from normal human urine and its cleavage by human uropepsin. J. Biol. Chem. 285, 1317–1329

39. Nentwich, H. A., Mustafa, Z., Rugg, M. S., Marsden, B. D., Cordell, M. R., He, H., Li, W., Chen, Y. T., Hayashida, Y., and Tseng, S. C. (2008) Reversal of trypsin inhibitor-factor-stimulated gene-6, in cervical smooth muscle cells by tumor necrosis factor-alpha stimulation. J. Biol. Chem. 283, 12699–12710

40. Higa, K., Shimmura, S., Shimazaki, J., and Tsubota, K. (2005) Hyaluronic acid is mediated by a factor produced by granulosa cells. J. Biol. Chem. 280, 573–580

41. Bourguignon, J., Borghi, H., Sesboüé, R., Diarra-Mehrpour, M., and Martin, J. P. (1994) Post-translational processing of the inter-α-trypsin inhibitor in the human hepatoma HepG2 cell line. Biochem. J. 302, 573–580

42. Li, W., He, H., Chen, Y. T., Hayashida, Y., and Tseng, S. C. (2008) Suppression of activation and induction of apoA-I, TSG-6, and HC-HA Expression by Amniotic Membrane Cells. J. Biol. Chem. 283, 5121–5129

43. Chun, S. Y., Hayashiya, Y., Chen, M. Y., Xie, H. T., and Tseng, S. C. (2011) A new isolation method of human limbal progenitor cells by maintaining close association with their niche cells. Stem Cells 29, 1535–1542

44. Fujimoto, T., Savani, R. C., Watari, M., Day, A. J., and Johns, A. H. (1994) In vivo binding of human inter-α-trypsin inhibitor free heavy chains to hyaluronic acid. Biol. Chem. Hoppe Seyler 375, 521–526

45. Héron, A., Bourguignon, J., Callé, A., Borghi, H., Sesboüé, R., Diarra-Mehrpour, M., and Martin, J. P. (1994) Post-translational processing of the inter-α-trypsin inhibitor in the human hepatoma HepG2 cell line. Biochem. J. 302, 573–580

46. Sjöberg, E. M., and Fries, E. (1992) Biosynthesis of bikunin proteins in the human carcinoma cell line HepG2 and in primary human hepatocytes: polypeptide assembly by glycosaminoglycan. J. Biol. Chem. 270, 18700–18709

47. Bourguignon, J., Borghi, H., Sesboüé, R., Diarra-Mehrpour, M., and Martin, J. P. (1994) Post-translational processing of the inter-α-trypsin inhibitor in the human hepatoma HepG2 cell line. Biochem. J. 302, 573–580

48. Meinert, M., Eriksen, G. V., Petersen, A. C., Helming, R. B., Laurent, C., Uldbjerg, N., and Malmström, A. (2001) Proteoglycans and hyaluronan in human fetal membranes. Am. J. Obstet. Gynecol. 184, 679–685

49. Jessen, T. E., Odum, L., and Johnsen, A. H. (1994) Amniotic membrane transplantation for ocular surface reconstruction. Bioch. Rep. 21, 481–489

50. Bouchard, C. S., and John, T. (2004) Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocular Surface 2, 201–211

51. Dua, H. S., Gomes, J. A., King, A. J., and Maharajan, V. S. (2004) The amniotic membrane in ophthalmology. Surv. Ophthalmol. 49, 51–77

52. Tseng, S. C. (2001) Amniotic membrane transplantation for ocular surface reconstruction. Bioch. Rep. 21, 481–489

53. Tseng, S. C., Espana, E. M., Kawakita, T., DiPascale, M. A., Li, W., He, H., Liu, T.-S., Cho, T.-H., Gao, Y.-Y., Yeh, L.-K., and Liu, C.-Y. (2004) How does amniotic membrane work? Ocular Surface 2, 177–187

54. Muramatu, M., Mori, S., Matsuzaawa, Y., Horiguchi, Y., Nakashima, Y., and Tanaka, M. (1980) Purification and characterization of urinary trypsin inhibitor, UTI68, from normal human urine and its cleavage by human uropepsin. J. Biol. Chem. 285, 1317–1329

55. Nentwich, H. A., Mustafa, Z., Rugg, M. S., Marsden, B. D., Cordell, M. R., Mahoney, D. J., Jenkins, S. C., Dowling, B., Fries, E., Milner, C. M., Loughlin, J., and Day, A. J. (2002) A novel alleleic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module: chromosomal localization, frequency analysis, modeling, and expression. J. Biol. Chem. 277, 15354–15362

56. Li, W., He, H., Chen, Y. T., Hayashida, Y., and Tseng, S. C. (2008) Reversal of myofibroblasts by amniotic membrane stroma extract. J. Cell. Physiol. 215, 657–664

57. Chen, S. Y., Hayashiya, Y., Chen, M. Y., Xie, H. T., and Tseng, S. C. (2011) A new isolation method of human limbal progenitor cells by maintaining close association with their niche cells. Tissue Eng. Part C Methods 17, 537–548

58. Yoneda, M., Suzuki, S., and Kimata, K. (1990) Hyaluronic acid associated with the surfaces of cultured fibroblasts is linked to a serum-derived 85-kDa protein. J. Biol. Chem. 265, 5247–5257

59. Chen, Y., Li, W., Hayashiya, Y., He, H., Chen, S. Y., Tseng, D. Y., Kheirkhah, A., and Tseng, S. C. (2007) Human amniotic epithelial cells as novel feeder layers for promoting ex vivo expansion of limbal epithelial progenitor cells. Stem Cells 25, 1995–2005

60. Li, W., He, H., Chen, Y. T., Hayashiya, Y., and Tseng, S. C. (2008) Suppression of myofibroblasts by amniotic membrane stroma extract. Invest. Ophthalmo. Vis. Sci. 49, 4468–4475

61. Bost, F., Bourguignon, J., Martin, J. P., Sesboüé, R., Thiberville, L., and Diarra-Mehrpour, M. (1993) Isolation and characterization of the human inter-α-trypsin inhibitor heavy-chain H1 gene. Eur. J. Biochem. 218, 283–291

62. Bourguignon, J., Borghi, H., Sesboüé, R., Diarra-Mehrpour, M., Bernaudin, J. F., Météayer, J., Martin, J. P., and Thiberville, L. (1999) Immunohistochemical distribution of inter-α-trypsin inhibitor chains in normal and malignant human lung tissue. J. Histochem. Cytochem. 47, 1625–1632

63. Kehlen, A., Pachnio, A., Thiele, K., and Langner, J. (2003) Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: up-regulation of hyaluronan-binding protein TSG-6. Arthritis Res. Ther. 5, R186–R192

64. Higa, K., Shimamura, S., Shimazaki, J., and Tsubota, K. (2005) Hyaluronic acid-CD44 interaction mediates the adhesion of lymphocytes by amniotic membrane stroma. Cornea 24, 206–212

65. Meinert, M., Eriksen, G. V., Petersen, A. C., Helming, R. B., Laurent, C., Uldbjerg, N., and Malmström, A. (2001) Proteoglycans and hyaluronan in human fetal membranes. Am. J. Obstet. Gynecol. 184, 679–685
Iα1, TSG-6, and HC-HA Expression by Amniotic Membrane Cells

Milner, C. M., Day, A. J., and Sabokbar, A. (2008) TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation. *J. Biol. Chem.* **283**, 25952–25962

Roberts, S., Evans, H., Menage, J., Urban, J. P., Bayliss, M. T., Eisenstein, S. M., Rugg, M. S., Milner, C. M., Griffin, S., and Day, A. J. (2005) TNFα-stimulated gene product (TSG-6) and its binding protein, Iα1, in the human intervertebral disc: new molecules for the disc. *Eur. Spine J.* **14**, 36–42

Tan, K. T., McGrouther, D. A., Day, A. J., Milner, C. M., and Bayat, A. (2011) Characterization of hyaluronan and TSG-6 in skin scarring: differential distribution in keloid scars, normal scars, and unscared skin. *J. Eur. Acad. Dermatol. Venereol.* **25**, 317–327

Tan, K. T., Baildam, A. D., Juma, A., Milner, C. M., Day, A. J., and Bayat, A. (2011) Hyaluronan, TSG-6, and inter-α-inhibitor in periprosthetic breast capsules: reduced levels of free hyaluronan and TSG-6 expression in contracted capsules. *Aesthetic Surg. J.* **31**, 47–55

Toda, A., Okabe, M., Yoshiida, T., and Nikaido, T. (2007) The potential of amniotic membrane/amoion-derived cells for regeneration of various tissues. *J. Pharmacol. Sci.* **105**, 215–228

Yu, S. J., Soncini, M., Kaneko, Y., Hess, D. C., Parolini, O., and Borlongan, C. V. (2009) Amnion: a potent graft source for cell therapy in stroke. *Cell Transplant.* **18**, 111–118

Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., and Prockop, D. J. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells emobilized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* **5**, 54–63

Camaioni, A., Hascall, V. C., Yanagishita, M., and Salustri, A. (1993) Effects of exogenous hyaluronic acid and serum on matrix organization and stability in the mouse cumulus cell-oocyte complex. *J. Biol. Chem.* **268**, 20473–20481

Chen, L., Mao, S. J., McLean, L. R., Powers, R. W., and Larsen, W. J. (1994) Proteins of the inter-α-trypsin inhibitor family stabilize the cumulus extracellular matrix through their direct binding with hyaluronic acid. *J. Biol. Chem.* **269**, 28282–28287

Nagyova, E., Camaioni, A., Prochazka, R., and Salustri, A. (2004) Covalent transfer of heavy chains of inter-α-trypsin inhibitor family proteins to hyaluronan in *in vivo* and *in vitro* expanded porcine oocyte-cumulus complexes. *Biol. Reprod.* **71**, 1838–1843